Strategic Planning
Operator-Led Strategic Planning for Biopharma Companies
Strategic planning in biopharma is not a slide deck exercise. It is a series of high-stakes decisions — about capital allocation, pipeline prioritization, commercial timing, and organizational design — that determine whether a company reaches its potential or falls short of it.
At Katogen, we bring 35+ years of operator experience to every strategic planning engagement. We have built companies from the ground up, turned around organizations in crisis, and navigated the full range of inflection points that growth-stage and mid-sized biopharma companies face. Our strategic advice is grounded in that experience — not in frameworks built from the outside.
What We Do
Strategic Roadmap Development We work with your executive team to build a clear, prioritized roadmap from where you are to where you need to be. That means honest assessment of your current position, identification of the key strategic choices ahead, and a plan that is ambitious enough to create real value and realistic enough to execute.
Portfolio Prioritization Which assets do you advance? Which partnerships do you pursue? Which markets do you enter first? We help leadership teams make these decisions with rigor and conviction — not by consensus or inertia.
Competitive Positioning We analyze your competitive landscape with the same depth a sophisticated acquirer or investor would apply — and help you build a positioning strategy that differentiates you meaningfully in a crowded field.
Organizational Design Strategy without the right organizational structure is a document, not a plan. We help you design the leadership team, governance model, and operating cadence needed to execute at the pace your strategy demands.
Board and Investor Alignment We help CEOs and executive teams translate strategy into narratives that align boards, attract capital, and build investor confidence — drawing on direct experience as a board member, CEO, and capital raiser.
Who This Is For
This service is designed for CEOs and executive teams at growth-stage and mid-sized biopharma and life sciences companies facing a strategic inflection point — a new financing round, a pipeline decision, a market entry, a leadership transition, or simply the recognition that the current strategy is not working fast enough.
Why Katogen
Most strategy advisors approach biopharma from the outside — with frameworks, benchmarks, and slide templates. Katogen approaches it from the inside — with 35+ years of experience sitting in the CEO chair, making the same decisions you are facing now.
That means our strategic plans are designed to be executed, not presented. Every recommendation is grounded in operational reality, not theoretical optionality.